Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the testosterone replacement therapy market. 

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health. 

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market. 

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company.

Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows.

The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst actions. 

Here are four stocks to buy now that could offer investors upside in both the short and long term.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Hims & Hers, which boasts a $9.7 billion market cap, is up 170% over the past year, though it's pulled back nearly 25% this past month.

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology stocks, starting with Hims & Hers Health (NYSE:HIMS).

Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income.

As the value of your investment portfolio rises over time, you will also be better equipped for retirement.

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week. 

Hims & Hers Health shares are trading lower Tuesday after GoodRx announces a collaboration with Novo Nordisk.

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

Motley Fool Money checks in on some stock market news.